Kymera Therapeutics, Inc. (KYMR) short interest & options flow
NASDAQKymera Therapeutics goes into its November 5 results with the stock up 11% in a single week, a wave of analyst target increases still landing, and options positioning that has turned noticeably more call-heavy, an unusual alignment for a clinical-stage biotech carrying 12.8% short interest. The options shift is the sharpest near-term signal. The put/call ratio has dropped to 0.79…
KYMR Wolfe Research upgrade to Outperform lifts stock as biotech gains analyst momentum. Consensus now "buy" with 16 analysts backing, $134.71 mean price target. Short interest 14.8% of float, down slightly from month ago.
- Market cap
- $11.63B
- Next earnings
- 5 Nov 2026
Key data as of 5 Nov 2026
KYMR news and analysis
RSSNo long-form analysis yet for KYMR. Pulse alerts and the live data picture are available on ORTEX.
Open KYMR on ORTEX →Want the live picture for KYMR?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KYMR — free to start on ORTEX.
Sign up for free →Open KYMR on ORTEX